CDB-4124 (proposed trade names Proellex, Progenta) is an investigational selective progesterone receptor modulator, tested for treatment of progesterone sensitive myomata.[1]
As of September 2008[update], it is undergoing Phase II and III clinical trials.[2]
References
- ^ Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone". J Steroid Biochem Mol Biol 88 (3): 277–88. doi:10.1016/j.jsbmb.2003.12.004. PMID 15120421.
- ^ ClinicalTrials.gov
|
